N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
N/A N=80 Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
Acute Ischemic Stroke (AIS)
Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes
Phase 2 N=323 Low Vision Intervention Trial II (LOVIT II)
Central Vision Loss From Macular Diseases
Primary: Comparison of Changes in Visual Reading Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire — 1.29; 0.95…
N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
N/A N=5 Prism Adaptation in Left Brain Stroke
Aphasia · Spatial Neglect · Stroke
Primary: Client Satisfaction Questionnaire — 32; 27 score on a scale
N/A N=129 Stroke Ready: A Stroke Preparedness Brief Intervention
Stroke
Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale
N/A N=258 Stroke Self-Management: Effect on Function and Stroke Specific Quality of Life
Stroke
Primary: Total Stroke Specific Quality of Life — 3.80; 3.82; 4.01; 3.94 units on a scale — p=0.0500
N/A N=284 Stroke Swallowing Screening Tool Validation
Cerebrovascular Disorders · Deglutition Disorders
Primary: Sensitivity of Screening Items — 37.9; 3.5; 62.1; 10.3 percentage of agreement
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
Phase 2 N=81 Bolus of Saline in Stroke
Ischemic Stroke
Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=222 Stroke Team Remote Evaluation Using a Digital Observation Camera
Stroke
Primary: Appropriateness of Decision to Treat or Not Treat With Thrombolytics — 98; 82 percentage of participants
Phase 2 N=241 Normal Saline Infusion for Stroke After Intravenous Thrombolysis
Brain Infarct
Primary: Number of Participants With 90-day Favorable Outcome — 106; 93 Participants
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Phase 3 N=3,876 Insulin Resistance Intervention After Stroke Trial
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
Phase 2 N=22 Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Non-arteritic Ischemic Optic Neuropathy · Optic Nerve Injuries
Primary: Mean Increase From Baseline in ETDRS Letters Read at 26 Weeks and Off-drug Follow-up Visit — 15; 7; 9; 6 EDTRS Letters
Phase 3 N=682 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
Macular Edema, Cystoid · Retinal Vein Occlusion
Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…
N/A N=52 Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Phase 3 N=188 Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Age-related Macular Degeneration · Depression
Primary: Depression — 11; 18; 5; 11 participants — p=.067
Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
Phase 2 N=162 Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
Stroke · Rhabdomyolysis · Jaundice
Primary: Total Number of Participants With an Increase in Liver Function Tests (LFTs) — 1; 2 Participants
Phase 2 N=16 Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
Central Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Systemic Adverse Events — 1; 0; 0; 1 participants
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
N/A N=75 Stroke Team Remote Evaluation Using a Digital Observation Camera- Long Term Outcomes(STRokE DOC-LTO)
Telemedicine Evaluation vs Telephone Evaluation
Primary: Functional Outcome (mRS(0-1)) at 6 Months After Index Event. The mRS is the Modified Rankin Scale That Measures Patient's Functional Level of Activity. The Scale is a 6…
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
Phase 2 N=40 Safety of Intravenous Thrombolysis for Wake-up Stroke
Ischemic Stroke
Primary: Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients — 0 cases.